Two cases of pancytopenia with Coombs-negative hemolytic anemia after chimeric antigen receptor T-cell therapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: International Journal of Molecular Sciences (2021) 22:11, 5449. https://doi.org/10.3390/ijms22115449
- Ereignis
-
Veröffentlichung
- (wo)
-
Würzburg
- (wer)
-
Universität Würzburg
- (wann)
-
2023
- Urheber
-
Kiem, Dominik
Leisch, Michael
Neureiter, Daniel
Haslauer, Theresa
Egle, Alexander
Melchardt, Thomas
Topp, Max S.
Greil, Richard
- DOI
-
10.3390/ijms22115449
- URN
-
urn:nbn:de:bvb:20-opus-284977
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:52 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kiem, Dominik
- Leisch, Michael
- Neureiter, Daniel
- Haslauer, Theresa
- Egle, Alexander
- Melchardt, Thomas
- Topp, Max S.
- Greil, Richard
- Universität Würzburg
Entstanden
- 2023
Ähnliche Objekte (12)
Approaches to improve outcome of hepatitis B virus-specific chimeric antigen receptor T-cell therapy
Optimization of chimeric antigen receptor (CAR) therapy
A two-chain chimeric antigen receptor (CAR) scaffold recruits endogenous CD3 for superior T-cell function
Chimeric Antigen Receptor T Cell Research For Clinical Applications
Chimeric antigen receptor T cells for acute myeloid leukemia
Chimeric antigen receptor T cell therapy to target lymphoid neoplasms
Improving Chimeric Antigen Receptor Design and Therapy for Treatment of Cancer
Improvement of Chimeric Antigen Receptor-Specific T Cells for Adoptive T Cell Transfer
Refined generation of chimeric antigen receptor T cells by dasatinib and urolithin A
Improvement of chimeric antigen receptor T cell therapy for patients with hematological malignancies
Targeting and Elimination of T Cell Subpopulations by Chimeric Antigen Receptor-modified T Cells
Chimeric antigen receptor-modified NK cells target breast carcinomas resistant to soluble antibody treatment
Approaches to improve outcome of hepatitis B virus-specific chimeric antigen receptor T-cell therapy
Optimization of chimeric antigen receptor (CAR) therapy
A two-chain chimeric antigen receptor (CAR) scaffold recruits endogenous CD3 for superior T-cell function
Chimeric Antigen Receptor T Cell Research For Clinical Applications
Chimeric antigen receptor T cells for acute myeloid leukemia
Chimeric antigen receptor T cell therapy to target lymphoid neoplasms
Improving Chimeric Antigen Receptor Design and Therapy for Treatment of Cancer
Improvement of Chimeric Antigen Receptor-Specific T Cells for Adoptive T Cell Transfer
Refined generation of chimeric antigen receptor T cells by dasatinib and urolithin A
Improvement of chimeric antigen receptor T cell therapy for patients with hematological malignancies
Targeting and Elimination of T Cell Subpopulations by Chimeric Antigen Receptor-modified T Cells
Chimeric antigen receptor-modified NK cells target breast carcinomas resistant to soluble antibody treatment
Approaches to improve outcome of hepatitis B virus-specific chimeric antigen receptor T-cell therapy
Optimization of chimeric antigen receptor (CAR) therapy
A two-chain chimeric antigen receptor (CAR) scaffold recruits endogenous CD3 for superior T-cell function
Chimeric Antigen Receptor T Cell Research For Clinical Applications
Chimeric antigen receptor T cells for acute myeloid leukemia
Chimeric antigen receptor T cell therapy to target lymphoid neoplasms
Improving Chimeric Antigen Receptor Design and Therapy for Treatment of Cancer
Improvement of Chimeric Antigen Receptor-Specific T Cells for Adoptive T Cell Transfer
Refined generation of chimeric antigen receptor T cells by dasatinib and urolithin A
Improvement of chimeric antigen receptor T cell therapy for patients with hematological malignancies
Targeting and Elimination of T Cell Subpopulations by Chimeric Antigen Receptor-modified T Cells